Contract facts
UnrestrictedRESEARCH AND DEVELOPMENT TO SUPPORT VERIOX DECONTAMINATION KIT TO TREAT CHEMICAL WEAPON AGENTS. is a federal Unrestricted award for Defense Threat Reduction Agency held by Armis Biopharma, Inc. Estimated value $20.3M ($4.8M obligated). Current period of performance ends Aug 8, 2025 (potential Feb 8, 2028). Last award drew 2 bidders. Place of performance: FORT COLLINS CO. Related solicitation HDTRA120S0001.
RESEARCH AND DEVELOPMENT TO SUPPORT VERIOX DECONTAMINATION KIT TO TREAT CHEMICAL WEAPON AGENTS.
Recompete timing
PublicCurrent PoP ended Aug 8, 2025 (415 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on HDTRA123C0013? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordArmis Biopharma, Inc — $4.8M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HDTRA123C0013?
HDTRA123C0013 (Research and development to support) is a Defense Threat Reduction Agency award with a potential value of $20.3M, currently held by Armis Biopharma, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HDTRA1-23-C-0013?
HDTRA1-23-C-0013 is the dashed form of PIID HDTRA123C0013 (Research and development to support), held by Armis Biopharma, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HDTRA123C0013?
Defense Threat Reduction Agency awarded HDTRA123C0013 to Armis Biopharma, Inc (potential $20.3M).
Who is the incumbent on HDTRA123C0013?
Armis Biopharma, Inc is the incumbent with $4.8M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 8, 2025.
When does Armis Biopharma, Inc’s HDTRA123C0013 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 8, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HDTRA123C0013? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.